Insulin Clearance Is Associated with Hepatic Lipase Activity and Lipid and Adiposity Traits in Mexican Americans

Artak Labadzhyan¹, Jinrui Cui¹, Miklós Péterfy², Xiuqing Guo³, Yii-Der I. Chen³, Willa A. Hsueh⁴, Jerome I. Rotter³, Mark O. Goodarzi¹*

¹ Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, United States of America, ² Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, United States of America, ³ Institute for Translational Genomics and Population Sciences, Los Angeles BioMedical Research Institute, Harbor-UCLA Medical Center, Torrance, California, United States of America, ⁴ Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, The Ohio State University, Columbus, Ohio, United States of America

* mark.goodarzi@cshs.org

Abstract

Reduction in insulin clearance plays an important role in the compensatory response to insulin resistance. Given the importance of this trait to the pathogenesis of diabetes, a deeper understanding of its regulation is warranted. Our goal was to identify metabolic and cardiovascular traits that are independently associated with metabolic clearance rate of insulin (MCRI). We conducted a cross-sectional analysis of metabolic and cardiovascular traits in 765 participants from the Mexican-American Coronary Artery Disease (MACAD) project who had undergone blood sampling, oral glucose tolerance test, euglycemic-hyperinsulinemic clamp, dual-energy X-ray absorptiometry, and carotid ultrasound. We assessed correlations of MCRI with traits from seven domains, including anthropometry, biomarkers, cardiovascular, glucose homeostasis, lipase activity, lipid profile, and liver function tests. We found inverse independent correlations between MCRI and hepatic lipase (P = 0.0004), insulin secretion (P = 0.0002), alanine aminotransferase (P = 0.0045), total fat mass (P = 0.014), and diabetes (P = 0.03). MCRI and apolipoprotein A-I exhibited a positive independent correlation (P = 0.035). These results generate a hypothesis that lipid and adiposity associated traits related to liver function may play a role in insulin clearance.

Introduction

The pathogenesis of type 2 diabetes involves an interplay of genetics and environment that results in insulin resistance and beta cell dysfunction. Insulin resistance is associated with obesity, elevated free fatty acids, and genetic defects [1]. Maintenance of normal glucose tolerance in the face of insulin resistance is dependent on the compensatory increase in circulating insulin levels to overcome insulin resistance; when this compensation is insufficient, diabetes develops. Compensatory hyperinsulinemia is not only related to increased insulin secretion by pancreatic β-cells but also to reduction in insulin clearance [2].
Insulin clearance is mainly carried out by the liver and kidneys as well as by uptake and degradation peripherally by insulin sensitive tissues [3]. Factors influencing insulin clearance include obesity, distribution of adiposity, fatty acids, glucose, catecholamines, and other hormones including growth hormone and sex hormones [3–5].

The metabolic clearance rate of insulin (MCRI) has been shown to be a highly heritable trait that can influence the risk of developing diabetes [6]. A genome-wide association study (GWAS) found that variants near the IDE and HHEX genes were associated with risk of type 2 diabetes [7]. While follow-up studies suggested variation in this locus may affect insulin secretion [8, 9], an effect on insulin clearance remains possible. A Metabochip study found that seven loci previously associated with type 2 diabetes were associated with insulin clearance [10]. To date, the only published GWAS of insulin clearance identified a variant in the GNA15 gene that nearly met genome-wide significance [11].

In a study of Hispanics and African Americans, lower insulin clearance at baseline was associated with a higher risk of incident diabetes at five years of follow-up [12]. However, an independent association has been difficult to establish given the many possible confounding factors and the lack of multivariate studies looking at traits across a wide spectrum of categories.

Our aim was to determine the association with MCRI of metabolic and cardiovascular traits within several phenotypic domains and to identify which of these traits are independently correlated with insulin clearance. By identifying unique traits associated with MCRI, our hope was also to gain insight on the underpinnings of insulin clearance that to date have not been clearly elucidated. The breadth of traits examined allowed the generation of new hypotheses.

Materials and Methods

Subjects

Metabolic and cardiovascular phenotypes were measured in subjects participating in the UCLA/Cedars-Sinai Mexican-American Coronary Artery Disease (MACAD) project, a study of Mexican-American families living in Los Angeles [6]. Subjects had to report at least three grandparents of Mexican origin to be classified as Mexican and qualify for the study. In the current report, we studied 765 subjects from 193 families (57% female and 43% male) with insulin clearance values, consisting of adult offspring (age 18 or older) of probands with coronary artery disease, and the spouses of those offspring (if available). By design, detailed phenotyping was performed only in the offspring and their spouses, who were free of overt cardiovascular and metabolic disease, to avoid secondary changes in phenotype caused by overt disease. Patients were free of major medical illness and none were taking glucocorticoids or antihyperglycemic agents that could affect glucose homeostasis.

Phenotyping procedures

Subjects underwent a three-day phenotyping protocol that included anthropometry, biomarkers, cardiovascular traits, glucose homeostasis indices, lipase activity, lipid parameters, and liver function tests. On one day, subjects gave fasting blood and underwent a 75 g oral glucose tolerance test (OGTT). On a different day, common carotid artery intima-media thickness (IMT) was measured by B-mode ultrasound and body fat distribution was assessed by dual-energy X-ray absorptiometry (DXA) scan. On a further day, subjects underwent a euglycemic-hyperinsulinemic clamp.

Fasting lipid parameters examined included total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), free fatty acids (FFA), and apolipoproteins (apoA-I, apoA-II, apoB). Fasting biomarkers included C-
reactive protein (CRP), adiponectin, and plasminogen activator inhibitor-1 (PAI-1) levels. Liver function tests included aspartate aminotransferase (AST) and alanine aminotransferase (ALT).

Homeostasis model assessment of steady state beta cell function (HOMA-%B) was derived from fasting glucose and insulin using the updated HOMA2 calculator at https://www.dtu.ox.ac.uk/homacalculator/. Insulinogenic index at 30 minutes (IGI30, pmol·l⁻¹·mmol⁻¹·l⁻¹), a commonly used index of acute insulin secretion, was calculated from the OGTT data as the change in insulin (0 to 30 min) divided by change in glucose (0 to 30 min). At the beginning of the clamp, a priming dose of human insulin (Novolin, Clayton, NC) was given. This was followed by infusion of insulin for 120 minutes at a constant rate (60 mU·m⁻²·min⁻¹) with the goal of achieving steady state plasma insulin levels of 100 mIU/ml or greater [13, 14]. Guided by blood sampling every 5 minutes, the rate of a simultaneous 20% dextrose infusion was adjusted to maintain plasma glucose concentrations at 95 to 100 mg/dl. The glucose infusion rate (M value, μmol·m⁻²·min⁻¹) during the last 30 minutes of steady-state glucose and insulin levels reflects glucose uptake by all tissues of the body (mainly insulin-mediated glucose uptake in muscle) and is directly correlated with tissue insulin sensitivity [14]. Often, an insulin sensitivity index (M/I, mg·m⁻²·min⁻¹·μIU⁻¹·mL) is calculated as M divided by the steady state plasma insulin level (I). In this study, to clearly distinguish between insulin sensitivity and insulin clearance in multivariate analyses, we relied on M as an approximation for insulin sensitivity in our primary analyses because the calculations of M/I and insulin clearance both use steady-state insulin in the denominator. The metabolic clearance rate of insulin (MCRI, mL·m⁻²·min⁻¹) was calculated as the insulin infusion rate divided by the insulin concentration during the steady state of the euglycemic clamp, as previously described [6, 14].

Cardiovascular phenotypes consisted of systolic and diastolic blood pressure (SBP and DBP), pulse, and carotid intima-media thickness (IMT) [15]. At the University of Southern California Atherosclerosis Research Unit, carotid artery images were acquired by high-resolution B-mode ultrasound using the Toshiba SSH-140A ultrasound system with a 7.5-MHz probe [16]. The IMT measure corresponds to the distance between the blood-intima and media-adventitia echoes obtained at the right distal common carotid artery [16]. The IMT values are reported as the average of 80 to 100 individual measurements made along 1 cm of the right distal common carotid artery [16].

Lipase activity included hepatic lipase (HL) and lipoprotein lipase measurements after heparin administration, as previously described [17]. Also tested were total fat mass and total lean mass measured by DXA, as well as anthropometric indices (BMI, height, weight, waist circumference, hip circumference) [18].

Ethics statement

All studies were approved by Human Subjects Protection Institutional Review Boards at UCLA and Cedars-Sinai Medical Center. All subjects gave written informed consent prior to participation.

Statistical analysis

When necessary, log-transformed (hip circumference, BMI, adiponectin, CRP, IMT, pulse, apoA-I, apoA-II, apoB, HDL-C, TG, ALT, AST, HOMA-%B, IGI30, 2-hr plasma glucose during OGTT, 2-hr plasma insulin during OGTT) or square-root-transformed (total fat mass, PAI-1, FFA, M value, hepatic lipase, lipoprotein lipase, MCRI) trait values were used to normalize the distribution for statistical analyses. Categorical traits (sex and diabetes status) were coded as 0 and 1 prior to inclusion in analyses. Traits were categorized into seven domains:
Lipid and Adiposity Traits and Insulin Clearance

Results

The clinical characteristics of the 765 subjects are shown in Table 1. Participants had a median age of 34 years and 57% were women. Subjects were generally healthy with normal range median systolic and diastolic blood pressure, pulse, lipid profile, and liver function tests. Only 3% of participants had diabetes as diagnosed by oral glucose tolerance testing.

Traits in the anthropometry domain that were significantly correlated with MCRI in the univariate analysis included waist, hip, BMI, total fat mass, and total lean mass (Table 1). In multivariate analysis, only fat mass remained significant (Table 2). Traits with significant correlation within the glucose homeostasis group were M value, IGI30, insulin at 120 minutes of

Fig 1. Three stages of statistical analyses. All analyses were done with MCRI as the dependent variable. Traits that were significant in univariate analysis were included in the multivariate analyses within each domain. The overall multivariate analysis included traits that were significant from each of the within-domain analyses. *Domains include anthropometry, biomarkers, cardiovascular, glucose homeostasis, lipase activity, lipid profile, and liver function tests.

doi:10.1371/journal.pone.0166263.g001
the OGTT, HOMA-%B, and diabetes status, the latter two of which also remained significant in multivariate analysis in this domain. Only hepatic lipase was significantly correlated with

| Domain/Trait | Median (IQR)a | r | P-value |
|--------------|---------------|---|---------|
| MCRI (mL·m⁻²·min⁻¹) | 468.8 (143.6) | n/a | n/a |

**ANTHROPOMETRY**

| Trait | Median (IQR) | r | P-value |
|-------|--------------|---|---------|
| Age (years) | 34.0 (13.0) | 0.0095 | 0.83 |
| Sex (% female) | 56.3 | -0.050 | 0.45 |
| Waist circumference (cm) | 91.8 (16.0) | -0.26 | <0.0001 |
| Hip circumference (cm) | 104.0 (12.5) | -0.24 | <0.0001 |
| Body mass index (BMI) (kg/m²) | 28.2 (6.3) | -0.27 | <0.0001 |
| Height (cm) | 162.0 (13.0) | -0.029 | 0.41 |
| Total fat mass (kg) | 23.9 (11.1) | -0.29 | <0.0001 |
| Total lean mass (kg) | 50.6 (18.8) | -0.12 | 0.0014 |

**BIOMARKERS**

| Trait | Median (IQR) | r | P-value |
|-------|--------------|---|---------|
| Plasminogen activator inhibitor-1 (PAI-1) (pmol/l) | 613.5 (536.5) | -0.15 | <0.0001 |
| Adiponectin (μg/ml) | 6.9 (4.3) | 0.080 | 0.044 |
| C reactive protein (CRP) (nmol/l) | 13.3 (19.0) | -0.057 | 0.24 |

**CARDIOVASCULAR**

| Trait | Median (IQR) | r | P-value |
|-------|--------------|---|---------|
| Carotid intima media thickness (mm) | 0.6 (0.1) | 0.0003 | 0.99 |
| Systolic blood pressure (SBP) (mmHg) | 112.3 (18.3) | -0.0086 | 0.79 |
| Diastolic blood pressure (DBP) (mmHg) | 66.7 (12.7) | -0.014 | 0.71 |
| Pulse (beats/min) | 69.3 (14.3) | -0.042 | 0.20 |

**GLUCOSE HOMEOSTASIS**

| Trait | Median (IQR) | r | P-value |
|-------|--------------|---|---------|
| M value (insulin sensitivity) [μmol·min⁻¹·m⁻²] | 1267.8 (830.4) | 0.14 | 0.0003 |
| HOMA-%B (%) | 120.0 (50.1) | -0.33 | <0.0001 |
| Insulinogenic index at 30 minutes (pmol·l⁻¹·mmol⁻¹·l) | 140.5 (140.5) | -0.19 | 0.0002 |
| Fasting glucose (mmol/l) | 5.14 (0.72) | 0.0088 | 0.83 |
| 2-hour glucose (mmol/l) | 6.16 (2.39) | -0.042 | 0.20 |
| 2-hour insulin (pmol/l) | 345.0 (405.0) | -0.20 | <0.0001 |
| Diabetes (%) | 2.6 | -0.33 | 0.0059 |

**LIPASE ACTIVITY**

| Trait | Median (IQR) | r | P-value |
|-------|--------------|---|---------|
| Hepatic lipase (nmol·ml⁻¹·min⁻¹) | 27.8 (19.2) | -0.17 | <0.0001 |
| Lipoprotein lipase (nmol·min⁻¹·min⁻¹) | 28.5 (32.2) | -0.033 | 0.47 |

**LIPID PROFILE**

| Trait | Median (IQR) | r | P-value |
|-------|--------------|---|---------|
| Total cholesterol (mg/dl) | 4.58 (1.19) | -0.036 | 0.37 |
| Low density lipoprotein cholesterol (LDL-C) (mmol/l) | 2.75 (0.97) | -0.054 | 0.18 |
| High density lipoprotein cholesterol (HDL-C) (mmol/l) | 1.16 (0.39) | 0.14 | 0.001 |
| Triglycerides (mmol/l) | 1.23 (1.03) | -0.10 | 0.0065 |
| Apolipoprotein A type I (apoA-I) (g/dl) | 1.11 (0.23) | 0.15 | 0.0002 |
| Apolipoprotein A type II (apoA-II) (g/dl) | 0.31 (0.06) | 0.017 | 0.69 |
| Apolipoprotein B (apoB) (g/dl) | 0.85 (0.32) | -0.081 | 0.035 |
| Non-esterified fatty acids (mmol/l) | 0.65 (0.31) | -0.011 | 0.74 |

**LIVER FUNCTION TESTS**

| Trait | Median (IQR) | r | P-value |
|-------|--------------|---|---------|
| Alanine transaminase (ALT) (μkat/l) | 0.38 (0.28) | -0.17 | <0.0001 |
| Aspartate transaminase (AST) (μkat/l) | 0.38 (0.15) | -0.13 | 0.001 |

Quantitative traits are presented as median (interquartile range (IQR)). Categorical traits (sex, diabetes) are presented as percent.

doi:10.1371/journal.pone.0166263.t001
MCRI from the lipase activity domain, with lipoprotein lipase not showing significant correlation. HDL-C, TG, and apoA-I were all significant in univariate analysis, but only apoA-I remained significant in multivariate analysis. Only biomarker PAI-1 was significant in univariate analysis. Both ALT and AST were significant in univariate analysis but only ALT remained significant in multivariate analysis. IMT, SBP, DBP, and pulse were not significant in univariate analysis.

In overall multivariate analysis, only diabetes, total fat mass, hepatic lipase, ALT, HOMA-%B, and apoA-I were significant (Table 3). Comparison of standardized coefficients allowed determination of the relative strength of each trait’s association with MCRI (listed strongest to weakest): diabetes (-0.28, P = 0.030), HOMA-%B (-0.22, P = 0.0002), hepatic lipase (-0.17, P = 0.0004), total fat mass (-0.12, P = 0.014), ALT (-0.12, P = 0.0045), and apoA-I (0.11, P = 0.035).

### Table 2. Multivariate analyses within each domain.

| Domain/Trait         | Standardized coefficient | Standard error | 95% confidence interval | P-value |
|----------------------|--------------------------|----------------|-------------------------|---------|
| **ANTHROPOMETRY**    |                          |                |                         |         |
| BMI                  | 0.019                    | 0.072          | -0.12                   | 0.16    | 0.79   |
| Waist                | -0.094                   | 0.074          | -0.24                   | 0.051   | 0.20   |
| Hip                  | 0.073                    | 0.066          | -0.056                  | 0.201   | 0.27   |
| Total fat mass       | -0.230                   | 0.079          | -0.45                   | -0.14   | 0.0002 |
| Total lean mass      | -0.071                   | 0.053          | -0.18                   | 0.034   | 0.183  |
| **GLUCOSE HOMEOSTASIS** |                        |                |                         |         |
| M value              | -0.0023                  | 0.054          | -0.11                   | 0.10    | 0.97   |
| IGI30                | -0.079                   | 0.046          | -0.17                   | 0.012   | 0.09   |
| Diabetes             | -0.38                    | 0.13           | -0.63                   | -0.14   | 0.0024 |
| HOMA-%B              | -0.29                    | 0.050          | -0.39                   | -0.19   | <0.0001|
| 2-hour insulin       | -0.058                   | 0.054          | -0.16                   | 0.048   | 0.29   |
| **LIPID PROFILE**    |                          |                |                         |         |
| HDL-C                | -0.024                   | 0.067          | -0.16                   | 0.11    | 0.72   |
| Triglycerides        | -0.11                    | 0.045          | -0.19                   | -0.017  | 0.019  |
| ApoA-I               | 0.16                     | 0.060          | 0.041                   | 0.28    | 0.008  |
| **LIVER FUNCTION TESTS** |                  |                |                         |         |
| ALT                  | -0.19                    | 0.059          | -0.30                   | -0.071  | 0.0015 |
| AST                  | 0.024                    | 0.063          | -0.10                   | 0.15    | 0.71   |

Variance inflation factors ranged from 2.44 to 5.16 for anthropometry; 1.07 to 2.08 for glucose homeostasis; 1.49 to 3.52 for lipid profile; and 2.67 to 2.89 for liver function tests.

doi:10.1371/journal.pone.0166263.t002

### Table 3. Overall multivariate analysis.

| Trait                | Standardized coefficient | Standard error | 95% confidence interval | P-value |
|----------------------|--------------------------|----------------|-------------------------|---------|
| Hepatic lipase       | -0.17                    | 0.048          | -0.26                   | -0.077  | 0.0004 |
| HOMA-%B              | -0.22                    | 0.059          | -0.33                   | -0.10   | 0.0002 |
| ALT                  | -0.12                    | 0.040          | -0.19                   | -0.036  | 0.0045 |
| Total fat mass       | -0.12                    | 0.050          | -0.22                   | -0.025  | 0.014  |
| Diabetes             | -0.28                    | 0.13           | -0.54                   | -0.027  | 0.030  |
| ApoA-I               | 0.11                     | 0.050          | 0.0075                  | 0.21    | 0.035  |
| PAI-1                | 0.0017                   | 0.040          | -0.076                  | 0.080   | 0.97   |

Variance inflation factors ranged from 1.02 to 2.24.

doi:10.1371/journal.pone.0166263.t003
To provide information on the clinical relevance of the final associations, Table 4 displays median MCRI values by quartile of the five quantitative traits that were significant in the overall multivariate analysis. Median MCRI was 444.9 mL m⁻² min⁻¹ (interquartile range 102.1) in the subjects with diabetes and 470.0 mL m⁻² min⁻¹ (IQR 145.2) in the subjects without diabetes.

### Discussion

In the current study of a wide spectrum of traits from Mexican-American families, we identified diabetes, insulin secretion, hepatic lipase, total fat mass, ALT, and apolipoprotein A-I as independent factors associated with insulin clearance.

To our knowledge, our study is the first to examine the direct association between hepatic lipase activity and insulin clearance. HL plays a key role in HDL metabolism by hydrolyzing triglycerides and phospholipids and helping produce smaller, more dense HDL particles [20]. It also helps facilitate binding and uptake by liver of cholesteryl esters from lipoproteins [21].

Increased HL activity has been associated with increased intra-abdominal fat content, obesity, insulin resistance, and diabetes [22, 23]. HL activity has also been shown to be positively correlated with severity of hepatic steatosis in non-alcoholic fatty liver disease [24]. Several studies have shown an inverse relationship between insulin clearance and liver fat content [25, 26]. In a large cohort of patients with nonalcoholic fatty liver disease and biopsy proven nonalcoholic steatohepatitis, mild increase in liver fat was associated with significantly impaired hepatic and whole body-insulin clearance [25].

Whether the hyperinsulinemic state seen in fatty liver is related to HL has not been studied. It may be that hepatic lipase’s influence on insulin clearance is related to its influence on the fat content of the liver. Given that increased ALT is a frequent marker of fatty liver disease, our finding of significant association between ALT and insulin clearance also supports this hypothesis. If insulin promotes hepatic lipase activity (as suggested by some studies but not others [27]), the negative relationship between insulin clearance and hepatic lipase activity may be related to higher insulin levels in individuals with lower insulin clearance. It is also possible that lower insulin clearance and increased hepatic lipase activity are consequences of fatty liver.

Liver function enzymes such as ALT and γ-glutamyltransferase (GGT) have been shown to predict incident type 2 diabetes [28]. Though the exact pathophysiology of this association is not fully understood, it is likely related to the liver’s significant role in glucose production and insulin metabolism [3]. Similar to our observations, other studies in healthy nondiabetic populations have demonstrated inverse relationships between ALT and endogenous clearance of insulin and/or hepatic insulin extraction [12, 29]. The relationship between impaired liver function and insulin clearance does not seem to be related to decreased insulin-degrading activity [30, 31] and warrants further investigation.
We observed a positive correlation between apolipoprotein A-I and MCRI. This correlation has not been previously explored and may provide a possible contributing mechanism in the pathogenesis of diabetes. ApoA-I is the major protein component of HDL and helps facilitate the process of reverse cholesterol transport [32, 33]. One explanation for the positive correlation in our study may be related to the effect of apoA-I on insulin secretion rather than a direct effect on insulin clearance [34]. However, both apoA-I and HOMA-%B remained significant in our overall multivariate analysis, which suggests that the effect of apoA-I on insulin clearance is independent of insulin secretion (with the caveat that HOMA-%B may not perfectly represent insulin secretion). Given the opposite directions of association seen between insulin resistance and insulin secretion and between insulin resistance and insulin clearance [2], the inverse relationship of HOMA-%B and MCRI in our study was expected.

Similar to our hypothesis for HL, the association of apoA-I with MCRI may be mediated through effects on liver fat content. ApoA-I deficient mice exhibited increased diet-induced hepatic triglyceride deposition, with gene transfer with apoA-I(Milano) resulting in significant reduction in hepatic triglyceride content and improvement in hepatic histology [35]. A similar inverse relationship of apoA-I and fatty liver was shown in patients with nonalcoholic steatohepatitis [36].

Though HDL-C and triglycerides were significantly associated with MCRI in univariate analysis, the significance was lost in multivariate analysis. Other studies have shown a positive correlation between HDL-C and MCRI; however, the multivariate models in these studies did not include apoA-I [12, 37]. The physical relationship of apoA-I and HDL may explain why HDL-C level did not correlate with MCRI when analyzed jointly.

The presence of diabetes correlated negatively with insulin clearance in the overall multivariate model. This is consistent with prior studies linking decreased insulin clearance with an adverse metabolic profile and increased risk of diabetes [4, 12, 37–39].

In the anthropometric domain of traits, we found an inverse correlation between total fat mass and MCRI. Previous studies have shown a significant negative correlation between BMI and insulin clearance [39, 40]; however, a recent study found no significant association between BMI and insulin clearance after accounting for insulin resistance [38]. A limitation in these studies has been the paucity of anthropometric traits evaluated. The findings from our multivariate analysis suggest that total fat mass is a better predictor of insulin clearance than BMI, waist circumference, or total lean mass.

Our study advances the field of the physiology of insulin clearance. While large scale studies have investigated the relationship of anthropometric, cardiovascular, glucose homeostasis, and lipid trait domains with insulin clearance derived from the frequently sampled intravenous glucose tolerance test [12, 37, 39], until now no extensive study looking at multiple domains had been performed using euglycemic clamp-derived insulin clearance. The availability of multiple traits in the MACAD cohort allowed interrogation of several key domains, including commonly available traits (e.g., BMI) as well as more unique traits (e.g., total fat mass). To our knowledge, this is the first euglycemic clamp study to examine the relationship of apolipoproteins, C-reactive protein, plasminogen activator inhibitor-1, and hepatic and lipoprotein lipase activities with insulin clearance. Most euglycemic clamp publications concerning insulin clearance have been conducted in small sample sizes, often less than 50 and rarely greater than 100 subjects. Our cohort of over 750 healthy subjects who underwent detailed physiologic phenotyping therefore represents a valuable contribution to this field. Our novel results include the identification within each trait domain of the traits independently associated with insulin clearance (e.g., total fat mass but not total lean mass). We also uniquely describe the independent negative associations of hepatic lipase activity and apolipoprotein A-I with insulin clearance.
Though the findings in our study are compelling, the results should be interpreted carefully. Limitations include the cross-sectional design and lack of longitudinal follow-up data, which limits our ability to infer causality. Because our measurement of MCRI reflects whole body insulin clearance, we were not able to separately study components of insulin clearance such as first pass hepatic extraction, renal clearance or peripheral tissue clearance. Liver fat was not measured in MACAD and may be an important consideration for future studies. Given that ALT is a poor surrogate for liver disease (e.g., patients with advanced non-alcoholic liver disease may have normal circulating liver enzymes), imaging studies to quantify liver fat would have allowed us to more accurately evaluate the role of hepatic steatosis in insulin clearance. Given that the kidneys also clear insulin, lack of renal functions tests is a limitation that should be addressed in future studies. As the current results were generated in a cohort of Mexican Americans, whether the findings apply to other ethnic groups is unknown.

Insulin clearance is an important component of insulin metabolism, with a decrease in clearance levels predicting increased incidence of type 2 diabetes [12]. We demonstrated for the first time that hepatic lipase was significantly and inversely associated with insulin clearance rate. The association between apoA-I and insulin clearance was also a novel finding. Further studies are needed to clarify the mechanisms of the above markers in insulin clearance and can provide potential therapeutic targets for prevention and treatment of diabetes. Our hypothesis-generating findings suggest mechanisms whereby lipid and adiposity factors related to liver function and structure may play important roles in insulin clearance.

Author Contributions

Conceptualization: AL MOG.
Data curation: XG MOG.
Formal analysis: AL JC XG MOG.
Funding acquisition: JIR WAH.
Investigation: Y-DIC WAH JIR.
Project administration: JIR WAH MOG.
Resources: XG Y-DIC WAH JIR.
Supervision: JIR WAH MOG.
Writing – original draft: AL MOG.
Writing – review & editing: MP JIR.

References

1. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006; 444(7121):840–6. Epub 2006/12/15. doi: 10.1038/nature05482 PMID: 17167471.
2. Mittelman SD, Van Citters GW, Kim SP, Davis DA, Dea MK, Hamilton-Wessler M, et al. Longitudinal compensation for fat-induced insulin resistance includes reduced insulin clearance and enhanced beta-cell response. Diabetes. 2000; 49(12):2116–25. PMID: 11118015.
3. Duckworth WC, Bennett RG, Hamel FG. Insulin degradation: progress and potential. Endocr Rev. 1998; 19(5):608–24. doi: 10.1210/edrv.19.5.0349 PMID: 9793760.
4. Marini MA, Frontoni S, Succiuro E, Arturi F, Fiorentino TV, Sciacqua A, et al. Differences in insulin clearance between metabolically healthy and unhealthy obese subjects. Acta Diabetol. 2014; 51(2):257–61. Epub 2013/08/31. doi: 10.1007/s00592-013-0511-9 PMID: 23989864.
5. Straznicky NE, Grima MT, Lambert EA, Sari CI, Eikelis N, Nestel PJ, et al. Arterial norepinephrine concentration is inversely and independently associated with insulin clearance in obese individuals with metabolic syndrome. J Clin Endocrinol Metab. 2015; 100(4):1544–50. doi: 10.1210/jc.2014-3796 PMID: 25590214.

6. Goodarzi MO, Taylor KD, Guo X, Quíñones MJ, Cui J, Li X, et al. Variation in the gene for muscle-specific AMP deaminase is associated with insulin clearance, a highly heritable trait. Diabetes. 2005; 54(4):1222–7. PMID: 15793265.

7. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature. 2007; 445(7130):881–5. doi: 10.1038/nature05616 PMID: 17293867.

8. Grarup N, Rose CS, Andersson EA, Andersen G, Nielsen AL, Albrechtsen A, et al. Studies of association of variants near the HHEX, CDKN2A/B, and IGF2BP2 genes with type 2 diabetes and impaired insulin release in 10,705 Danish subjects: validation and extension of genome-wide association studies. Diabetes. 2007; 56(12):3105–11. doi: 10.2337/db07-0556 PMID: 17827400.

9. Pascoe L, Tura A, Patel SK, Ibrahim IM, Ferrannini E, Zeggini E, et al. Common variants of the novel type 2 diabetes genes CDKAL1 and HHEX/IDE are associated with decreased pancreatic beta-cell function. Diabetes. 2007; 56(12):3101–4. doi: 10.2337/db07-0639 PMID: 17804762.

10. Goodarzi MO, Guo X, Cui J, Jones MR, Harttunians T, Xiang AH, et al. Systematic evaluation of validated type 2 diabetes and glycemic trait loci for association with insulin clearance. Diabetologia. 2013; 56(6):1282–90. doi: 10.1007/s00125-013-2880-6 PMID: 23494448; PubMed Central PMCID: PMC3685176.

11. Palmer ND, Goodarzi MO, Langeland CD, Wang N, Guo X, Taylor KD, et al. Genetic variants associated with quantitative glucose homeostasis traits translate to type 2 diabetes in Mexican Americans: the GUARDIAN (Genetics Underlying Diabetes in Hispanics) Consortium. Diabetes. 2015; 64(5):1853–66. Epub 2014/12/20. doi: 10.2337/db14-0732 PMID: 25524916; PubMed Central PMCID: PMC4407862.

12. Lee CC, Haffner SM, Wagenknecht LE, Lorenzo C, Norris JM, Bergman RN, et al. Insulin clearance and the incidence of type 2 diabetes in Hispanics and African Americans: the IRAS Family Study. Diabetes Care. 2013; 36(4):901–7. doi: 10.2337/dc12-1316 PMID: 23223351; PubMed Central PMCID: PMC3609510.

13. Goodarzi MO, Guo X, Taylor KD, Quíñones MJ, Saad MF, Yang H, et al. Lipoprotein lipase is a gene for insulin resistance in Mexican Americans. Diabetes. 2004; 53(1):214–20. PMID: 14693718.

14. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979; 237(3):E214–23. PMID: 382871.

15. Goodarzi MO, Taylor KD, Guo X, Quíñones MJ, Cui J, Li Y, et al. Association of the diabetes gene calpain-10 with subclinical atherosclerosis: the Mexican-American Coronary Artery Disease Study. Diabetes. 2005; 54(4):1228–32. PMID: 15793266.

16. Selzer RH, Mack WJ, Lee PL, Kwong-Fu H, Hodis HN. Improved common carotid elasticity and intramedia thickness measurements from computer analysis of sequential ultrasound frames. Atherosclerosis. 2001; 154(1):185–93. PMID: 11137099.

17. Goodarzi MO, Wong H, Quíñones MJ, Taylor KD, Guo X, Castellani LW, et al. The 3’ untranslated region of the lipoprotein lipase gene: haplotype structure and association with post-heparin plasma lipase activity. J Clin Endocrinol Metab. 2005; 90(8):4816–23. doi: 10.1210/jc.2005-0389 PMID: 15928243.

18. Li X, Quíñones MJ, Wang D, Bulnes-Enriquez I, Jimenez X, De La Rosa R, et al. Genetic effects on obesity assessed by bivariate genome scan: the Mexican-American coronary artery disease study. Obesity (Silver Spring). 2006; 14(7):1192–200. doi: 10.1038/oby.2006.136 PMID: 16899800.

19. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986; 42(1):121–30. PMID: 3719049.

20. Annema W, Tietge UJ. Role of hepatic lipase and endothelial lipase in high-density lipoprotein-mediated reverse cholesterol transport. Curr Atheroscler Rep. 2011; 13(3):257–65. doi: 10.1007/s11883-011-0175-2 PMID: 21424685; PubMed Central PMCID: PMC3085744.

21. Santamarina-Fojo S, Gonzalez-Navarro H, Freeman L, Wagner E, Nong Z. Hepatic lipase, lipoprotein metabolism, and atherogenesis. Arterioscler Thromb Vasc Biol. 2004; 24(10):1750–4. Epub 2004/07/31. doi: 10.1161/01.ATV.0000140818.00570.2d PMID: 15284087.

22. Carr MC, Hokanson JE, Zambon A, Deeb SS, Barrett PH, Purnell JQ, et al. The contribution of intra-abdominal fat to gender differences in hepatic lipase activity and low/high density lipoprotein heterogeneity. J Clin Endocrinol Metab. 2001; 86(6):2831–7. Epub 2001/06/09. doi: 10.1210/jcem.86.6.7586 PMID: 11397895.

23. Lewis GF, Murdoch S, Uffelman K, Naples M, Szeto L, Albers A, et al. Hepatic lipase mRNA, protein, and plasma enzyme activity is increased in the insulin-resistant, fructose-fed Syrian golden hamster
and is partially normalized by the insulin sensitizer rosiglitazone. Diabetes. 2004; 53(11):2893–900. Epub 2004/10/27. PMID: 15504970.

24. Miksztowicz V, Lucero D, Zago V, Cacciaguì L, Lopez G, Gonzalez Balldera E, et al. Hepatic lipase activity is increased in non-alcoholic fatty liver disease beyond insulin resistance. Diabetes Metab Res Rev. 2012; 28(6):535–41. doi: 10.1002/dmr.2212 PMID: 22539458.

25. Bril F, Lomonaco R, Orsak B, Ortiz-Lopez C, Webb A, Tio F, et al. Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis. Hepatology. 2014; 59(6):2178–87. doi: 10.1002/hep.26988 PMID: 24777953.

26. Kotronen A, Juurinen L, Tiikkainen M, Vehkavaara S, Yki-Järvinen H. Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes. Gastroenterology. 2008; 135(1):122–30. doi: 10.1053/j.gastro.2008.03.021 PMID: 18474251.

27. Perret B, Mable L, Martinez L, Terce F, Barbaras R, Collet X. Hepatic lipase: structure/function relationship, synthesis, and regulation. J Lipid Res. 2002; 43(8):1163–9. Epub 2002/08/15. PMID: 12177160.

28. Wannamethee SG, Shaper AG, Lennon L, Whincup PH. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care. 2005; 28(12):2913–8. PMID: 16306554.

29. Bonnet F, Ducluzeau PH, Gastaldelli A, Laville M, Anderwald CH, Konrad T, et al. Liver enzymes are associated with hepatic insulin resistance, insulin secretion, and glucagon concentration in healthy men and women. Diabetes. 2011; 60(6):1660–7. Epub 2011/04/28. doi: 10.2337/db10-1806 PMID: 21521874; PubMed Central PMCID: PMC3114399.

30. Auletta M, Antoniello S, Abrescia N. Insulin-degrading activity in experimental liver cirrhosis of the rat. Enzyme Protein. 1994; 48(4):197–201. PMID: 8821707.

31. Antoniello S, La Rocca S, Cavalcanti E, Auletta M, Salvatore F, Cacciatore L. Insulin and glucagon degradation in liver are not affected by hepatic cirrhosis. Clin Chim Acta. 1989; 183(3):343–50. PMID: 2680168.

32. Rader DJ. Regulation of reverse cholesterol transport and clinical implications. Am J Cardiol. 2003; 92(4A):42J–9J. PMID: 12957326.

33. Silver DL, Wang N, Xiao X, Tall AR. High density lipoprotein (HDL) particle uptake mediated by scavenger receptor class B type 1 results in selective sorting of HDL cholesterol from protein and polarized cholesterol secretion. J Biol Chem. 2001; 276(27):25287–93. doi: 10.1074/jbc.M101726200 PMID: 11301333.

34. Fryirs MA, Barter PJ, Appavo M, Tuch BE, Tabet F, Heather AK, et al. Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion. Arterioscler Thromb Vasc Biol. 2010; 30(8):1642–8. doi: 10.1161/ATVBAHA.110.207373 PMID: 20466975.

35. Karavia EA, Papachristou DJ, Lopeta K, Triantaphyllidou IE, Dimitrakopoulos O, Kypros KE. Apolipoprotein A-I modulates processes associated with diet-induced nonalcoholic fatty liver disease in mice. Mol Med. 2012; 18:901–12. doi: 10.2119/molmed.2012.00113 PMID: 22576368; PubMed Central PMCID: PMC3459476.

36. Gambino R, Cassader M, Pagano G, Durazzo M, Musso G. Polymorphism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profile in NASH? Hepatology. 2007; 45(5):1097–107. doi: 10.1002/hep.21631 PMID: 17464986.

37. Lee CC, Lorenzo C, Haffner SM, Wagenknecht LE, Goodarzi MO, Stefanovski D, et al. Components of metabolic syndrome and 5-year change in insulin clearance—the Insulin Resistance Atherosclerosis Study. Diabetes Obes Metab. 2013; 15(5):441–7. doi: 10.1111/dob.12049 PMID: 23216702; PubMed Central PMCID: PMC3531815.

38. Kim MK, Reaven GM, Chen YD, Kim E, Kim SH. Hyperinsulinemia in individuals with obesity: Role of insulin clearance. Obesity (Silver Spring). 2015; 23(12):2430–4. doi: 10.1002/oby.21256 PMID: 26524351; PubMed Central PMCID: PMC4701635.

39. Lichtash CT, Cui J, Guo X, Chen YD, Hsueh WA, Rotter JL, et al. Body adiposity index versus body mass index and other anthropometric traits as correlates of cardiometabolic risk factors. PLoS One. 2013; 8(6):e65954. doi: 10.1371/journal.pone.0065954 PMID: 23776578; PubMed Central PMCID: PMC3679008.